Spyre's anti-TL1A antibody SPY072 falls short in psoriatic arthritis and axial spondyloarthritis
- Spyre reported that SPY072, its anti-TL1A antibody, missed the primary endpoint in the psoriatic arthritis and axial spondyloarthritis parts of the Phase 2 SKYWAY basket trial.
- Safety was described as well tolerated and in line with the TL1A class.
- The company will stop developing the antibody in rheumatic diseases; an earlier rheumatoid arthritis cohort had also fallen below its internal bar.
- Focus shifts to hidradenitis suppurativa, in combination with an IL-17A/F inhibitor, with Week 16 data expected late 2027 or early 2028.
💡 Points Based on public reports
Three rheumatic cohorts, three disappointments, and TL1A's autoimmune story now looks like a gut-and-skin play rather than a platform for every inflammatory disease. That leaves Spyre leaning on hidradenitis suppurativa, where pairing with an IL-17A/F blocker is the real bet. Data not before late 2027 means a long wait on a narrowing thesis.